您的位置: 首页 > 农业专利 > 详情页

COMBINATION OF AN ANTI-VEGFR-2 ANTIBODY AND AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCER
专利权人:
MedImmune Ltd.;ImClone LLC
发明人:
Richard Brian GAYNOR,Maria KARASARIDES
申请号:
US16339776
公开号:
US20200062850A1
申请日:
2017.10.27
申请国别(地区):
US
年份:
2020
代理人:
摘要:
The present disclosure relates to a combination of anti-human VEGFR-2 antibodies (Ramucirumab) and anti-human PD-L1 (durvalumab) antibodies for treating certain disorders, including advanced gastric or gastroesophageal junction adenocarcinomas, non-small cell lung cancer, and hepatocellular carcinomas. Sequences 3 &; 4 represent Ramucirumab VL and VH; Sequences 7 &; 8 those of Durvalumab.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充